Signified and signifier

Signifier Medical Technologies Announces Publication of a New Study Exploring Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea

Retrieved on: 
Thursday, March 7, 2024
Health, Medical Devices, Health Technology, Other Health, General Health, Research, Science, Diabetes, Freedom, CPAP, Patient satisfaction, Sleep apnea, Quality of life, Quality-adjusted life year, Treatment, Obstructive sleep apnea, Continuous positive airway pressure, Technology assessment, ICER, Prevalence, Hypertension, Life imprisonment, PAP, Patient, Canadian International Council, NMES, Signified and signifier, DRS, Health technology

Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces that The International Journal of Technology Assessment in Health Care has recently published an exploratory analysis entitled " Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea ."

Key Points: 
  • Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces that The International Journal of Technology Assessment in Health Care has recently published an exploratory analysis entitled " Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea ."
  • Shan Liu, Jan Pietzsch, and a collaborative research team explores the cost-effectiveness of using neuromuscular electrical stimulation (NMES) as a treatment option for patients with mild obstructive sleep apnea (OSA).
  • The results of the exploratory analysis indicated that neuromuscular electrical stimulation may be a cost-effective treatment option for mild OSA compared to no treatment.
  • "We are excited to see the results of this study reinforce the potential of neuromuscular electrical stimulation as a revolutionary treatment option for individuals with mild obstructive sleep apnea," states Mujtaba Chohan, Head of Finance & Chief of Staff at Signifier.

Signifier Medical Technologies Announces Upcoming Publication of Randomized Controlled Trial Results Examining High-Intensity (Active) Vs. Low-Intensity (Sham) Neuromuscular Electrical Stimulation in Patients for 6 Weeks

Retrieved on: 
Thursday, November 2, 2023
Neurology, Venture Capital, Health, Medical Devices, Health Technology, Professional Services, Clinical Trials, Other Health, Supine position, NMES, Research, Clinical trial, Body mass index, Signified and signifier, PAP, Sleep, Somnolence, Health technology, Patient, Randomized controlled trial, Obstructive sleep apnea, AEGIS, Pharmaceutical industry, Birth control

The objective of the trial was to determine whether patients with mild obstructive sleep apnea (OSA) would adhere to eXciteOSA, a daytime neuromuscular electrical stimulation (NMES) therapy.

Key Points: 
  • The objective of the trial was to determine whether patients with mild obstructive sleep apnea (OSA) would adhere to eXciteOSA, a daytime neuromuscular electrical stimulation (NMES) therapy.
  • This trial demonstrates the potential of Signifier Medical’s innovative medical technology to significantly improve the lives of individuals suffering from obstructive sleep apnea (OSA).
  • The trial involved 40 patients and was conducted in collaboration with a network of renowned medical institutions and healthcare professionals.
  • Signifier Medical Technologies remains dedicated to further research, development, and collaboration with healthcare professionals to continue advancing medical technology and improving patient outcomes.

Signifier Medical Technologies Announces Conference Participation at CHEST 2022, Medtrade East and Maryland Sleep Society Annual Scientific Conference

Retrieved on: 
Tuesday, October 11, 2022
Health, FDA, Medical Devices, Health Technology, General Health, Research, Science, Tongue, Stroke, Somnolence, Patient, Sleep, OSA, Human, Research, Company, Health technology, Population health, Ageing, NMES, Placebo, Death, FDA, Signified and signifier, Solution, Pharmaceutical industry

Signifier Medical Technologies LLC (Signifier or the Company), a Boston-based medical technology company, announced participation in three upcoming medical conferences.

Key Points: 
  • Signifier Medical Technologies LLC (Signifier or the Company), a Boston-based medical technology company, announced participation in three upcoming medical conferences.
  • At each conference, Signifier will showcase its lead product eXciteOSA , the only FDA-authorized, non-invasive daytime therapy for primary snoring and mild obstructive sleep apnea.
  • In the companys booth at each conference, Signifier will have copies available of its recently released white paper, A descriptive analysis of objectively-monitored real-world adherence to eXciteOSA .
  • Details for the three conferences include:
    The Sheraton Baltimore North Hotel, Townson, Maryland
    Signifier is a pioneer in addressing the root causes of sleep disordered breathing.

Signifier Medical Technologies’ eXciteOSA®, the Only FDA-Authorized Daytime Therapy for Primary Snoring and Mild Obstructive Sleep Apnea, Demonstrates Real-World Adherence to Treatment of Over 80%

Retrieved on: 
Wednesday, September 21, 2022
FDA, Health Technology, Health, Medical Devices, Medical Affairs Bureau, Hypertension, Patient, Mask, Sleep, Research, Death, Placebo, Snoring, Company, Pittsburgh Sleep Quality Index, AHI, Obstructive sleep apnea, Continuous positive airway pressure, Health technology, Ageing, PAP, Risk, FDA, Sleep apnea, American Journal of Respiratory and Critical Care Medicine, Association, Population, Clinical trial, CPAP, Sama, Data, List of MDPI academic journals, Somnolence, Multi-Ethnic Study of Atherosclerosis, Marital status, Roy Taylor (scientist), American Journal, Epworth Sleepiness Scale, Stroke, NMES, Medicine, Mouth, Quality of life, Population health, Solution, Smoking, Multimedia, Education, Fasting, Pharmaceutical industry, Medical device, Signified and signifier, Atherosclerosis

The results demonstrate that patients have used eXciteOSA therapy on over 80% of days during the first six weeks of treatment.

Key Points: 
  • The results demonstrate that patients have used eXciteOSA therapy on over 80% of days during the first six weeks of treatment.
  • Sleep apnea is a serious condition, and adherence to treatment is both a challenge and a requirement.
  • We understand patients desire for effective treatments that fit their lifestyle, said Dr. Jessie Bakker, Executive Vice President of Medical Affairs at Signifier.
  • Signifier is dedicated to engaging with the sleep research community to produce high-quality evidence from rigorous clinical trials.

Signifier Medical Technologies is Granted HCPCS Codes for eXciteOSA to Help Patients Access Innovative Technology

Retrieved on: 
Tuesday, February 22, 2022
Biotechnology, Mental Health, Medical Devices, Health, Pharmaceutical, Diabetes, Center, Stroke, Obstructive sleep apnea, McNicholas, OSA, Hypertension, Literature review, Solution, Incidence, Snoring, Depression, The New England Journal of Medicine, Centers for Medicare & Medicaid Services, Hypopnea, Veni, vidi, vici, Man, Sleep apnea, LLC, Multimedia, Kotecha, Maintenance, Quality of life, DME, Population health, Medicare, Population, HCPCS, Moyamoya disease, NMES, Heart failure, Continuous positive airway pressure, Observational study, TIA, Sleep, Patient, Signified and signifier, CMS, Health, Physician, Death, Association, Sleep-related breathing disorder, PubMed, Meta-analysis, Electricity, Ageing, JAMA Internal Medicine, News, FDA, Lancet, Health technology, Cardiovascular disease, Medical device, Hospital, Pharmaceutical industry, Wood drying, Silviculture, Dudley Benjafield, Signifier Medical Technologies, eXciteOSA®, Snoring and Obstructive Sleep Apnea, SIGNIFIER MEDICAL TECHNOLOGIES, EXCITEOSA®, SNORING AND OBSTRUCTIVE SLEEP APNEA

We welcome CMS decision to establish two new codes to describe the eXciteOSA device, said Akhil Tripathi, Chief Executive Officer at Signifier.

Key Points: 
  • We welcome CMS decision to establish two new codes to describe the eXciteOSA device, said Akhil Tripathi, Chief Executive Officer at Signifier.
  • HCPCS codes play a critical role in providing patients with access to new medical devices, often improving payment options and healthcare decisions, said Dr. Marc Benton, a New Jersey-based pulmonologist and sleep medicine specialist.
  • The eXciteOSA is a non-invasive, easy to use therapy that does not require patients to wear any sort of device during the night.
  • Unlike other devices which are used while patients sleep, eXciteOSA is the first commercially available device used while awake.

Signifier Medical Technologies appoints two new senior members to the UK and USA organization

Retrieved on: 
Tuesday, July 21, 2020
Semiotics, Ferdinand de Saussure, Signified and signifier, Sleep apnea, Advertising, Strategic alliance, Branches of biology, Articles, Academic disciplines

Mr. Sharris appointed as Vice President of Sales for North America who will bring his strategic and commercial experience in respiratory and medical technologies to help guide Signifier Medical Technologies in the commercialization of its Snoozeal device in the region.

Key Points: 
  • Mr. Sharris appointed as Vice President of Sales for North America who will bring his strategic and commercial experience in respiratory and medical technologies to help guide Signifier Medical Technologies in the commercialization of its Snoozeal device in the region.
  • Mr. Saunders is appointed Head of Sales EMEA and will bring with him his extensive background in respiratory and medical technologies to help guide Signifier Medical Technologies in its commercialization of its sleep apnea devices.
  • "Today's announcement further builds upon the Signifier team globally'' said Anshul Sama, CMO and Co-Founder of Signifier Medical Technologies.
  • "Each person brings extensive medical technologies backgrounds to the business and will help Signifier strengthen channel partnerships, develop strategic alliances and expand our international sales presence."

Signifier Medical Technologies appoints two new senior members to the UK and USA organization

Retrieved on: 
Tuesday, July 21, 2020
Semiotics, Ferdinand de Saussure, Signified and signifier, Sleep apnea, Advertising, Strategic alliance, Branches of biology, Articles, Academic disciplines

Mr. Sharris appointed as Vice President of Sales for North America who will bring his strategic and commercial experience in respiratory and medical technologies to help guide Signifier Medical Technologies in the commercialization of its Snoozeal device in the region.

Key Points: 
  • Mr. Sharris appointed as Vice President of Sales for North America who will bring his strategic and commercial experience in respiratory and medical technologies to help guide Signifier Medical Technologies in the commercialization of its Snoozeal device in the region.
  • Mr. Saunders is appointed Head of Sales EMEA and will bring with him his extensive background in respiratory and medical technologies to help guide Signifier Medical Technologies in its commercialization of its sleep apnea devices.
  • "Today's announcement further builds upon the Signifier team globally'' said Anshul Sama, CMO and Co-Founder of Signifier Medical Technologies.
  • "Each person brings extensive medical technologies backgrounds to the business and will help Signifier strengthen channel partnerships, develop strategic alliances and expand our international sales presence."